GAITHERSBURG, MD., October 24 /CNW/ - Bridge Pharmaceuticals, Inc.
(Bridge), a contract research organization (CRO) providing GLP-compliant
preclinical drug development services in the US and China, announced the
appointment of Vincent S. Lagrotteria to Vice President of Global Sales and
Marketing, effective immediately. Mr. Lagrotteria brings to Bridge more than
20 years of healthcare sales experience in a wide variety of leadership
"When we saw the breadth of Vinny's experience and his exceptional sales
achievements, we were eager to have him join us," said Bridge CEO Tom Oakley.
"We are delighted to welcome him aboard."
"I am excited to join a company truly bridging East and West," said Mr.
Lagrotteria. "Only Bridge offers preclinical toxicology services in the US and
China fully compliant to international GLP standards. But that just scratches
the surface. Bridge's unique combination of comprehensive general toxicology
and hard-to-find specialty services along with years of scientific experience
creates unparalleled advantages for accelerating pharmaceutical development.
My goal is getting our full story in front of the customers."
Prior to Bridge, Mr. Lagrotteria was Vice President, Global Sales and
Marketing for Bilcare, a Phoenixville, PA provider of drug development
services in the US, India, and the UK. Earlier, he was Vice President, Global
Business Development, for Charles River Laboratories of Cary, NC and Senior
Vice President of Sales, Marketing and Strategic Initiatives, for Medifacts
International of Rockville, MD. His bachelor's degree in business is from
Towson State University. He earned his MBA and election to marketing honors
society Mu Kappa Tau at Loyola College of Maryland.
Bridge Pharmaceuticals, Inc. is one of the first preclinical contract
research organization (CRO) to provide US-level drug development services in
both Asia and the US. Bridge is headquartered in the United States with
laboratories in Gaithersburg, Maryland and Beijing, China. Bridge focuses on
providing cost-effective, high-quality FDA compliant drug development services
for pharmaceutical, biotech and government clients. Bridge's current
capabilities in preclinical drug development include GLP compliant toxicology,
safety pharmacology, pathology and bioanalytical services. For more
information, visit http://www.bridgecro.com.
For further information:
For further information: Bridge Pharmaceuticals, Inc. In USA: Marisa
Pawlewicz, 240-364-6249 firstname.lastname@example.org or In China: Tina Huang,